Management of chronic hepatitis C: consensus guidelines.
- 1 June 2007
- journal article
- review article
- Vol. 21, 25C-34C
Abstract
Since the last consensus conference on the management of chronic viral hepatitis, a number of studies looking at modifications of the standard course of treatment have been published. These changes have been sufficiently substantive to warrant review to determine whether any changes in the recommended treatment algorithms are needed. A consensus development conference was held in January 2007, and the present document highlights the results of the presentations and discussion about these issues. It reviews the epidemiology of hepatitis C in Canada, treatment of acute hepatitis C and new algorithms in chronic hepatitis C, including retreatment of previous treatment failures. In addition, sections on management of hepatitis C in special populations have been updated. There is also a section on the use of hematopoietic growth factors to help manage patients on therapy. The document should be read in conjunction with the previous document to identify changes. Some recommendations made in the previous document remain and are not discussed here.Keywords
This publication has 88 references indexed in Scilit:
- Injection drug use and the hepatitis C virus: Considerations for a targeted treatment approach-The case study of CanadaJournal of Urban Health, 2004
- Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for treatment of HIV/HCV co-infected patientsAIDS, 2004
- Peginterferon Alfa-2a plus Ribavirin for Chronic Hepatitis C Virus Infection in HIV-Infected PatientsNew England Journal of Medicine, 2004
- Peginterferon Alfa-2a plus Ribavirin versus Interferon Alfa-2a plus Ribavirin for Chronic Hepatitis C in HIV-Coinfected PersonsNew England Journal of Medicine, 2004
- A prospective controlled study of interferon-based therapy of chronic hepatitis C in patients on methadone maintenanceHepatology, 2004
- Hepatitis C virus infection and non‐hodgkin lymphoma: Results of the NCI‐seer multi‐center case‐control studyInternational Journal of Cancer, 2004
- Peg-Interferon Alfa 2a (40kDa) in patients on chronic haemodialysis with chronic C hepatitis. Preliminary results.2004
- Peginterferon alfa-2b plus ribavirin for treatment of chronic hepatitis C in previously untreated patients infected with HCV genotypes 2 or 3*1, *2Journal of Hepatology, 2004
- HIV and hepatitis C coinfection within the CAESAR studyHIV Medicine, 2004
- Treatment of chronic hepatitis C in patients with decompensated cirrhosis.2004